Biological Psychiatry Frontiers explores how genetics, neurocircuitry, immune pathways, and stress biology translate into new diagnostics and treatments across mood, psychotic, and anxiety disorders. This page connects discovery science to clinical impact—how target engagement links to symptoms, which biomarkers are closest to practice, and where precision approaches can refine selection and dosing. If you are scanning options like a biological psychiatry conference, you’ll find pragmatic guidance for integrating candidate markers, digital endpoints, and real-world evidence into service models without overpromising. Because circuits and molecules only matter when they guide care, we also cross-link to Precision Psychopharmacology so teams can align assays with medication decisions, outcomes, and patient-centred goals.

Implementation requires method discipline and equity. We outline how to evaluate biomarker readiness (analytical validity, clinical validity, clinical utility), set decision thresholds, and communicate uncertainty. We also cover immune–inflammation signatures, sleep and circadian markers, and neuroimaging measures that stratify risk or predict response, alongside ethics: privacy, data governance, and access. Digital phenotyping—passive sensing, speech, and keystroke dynamics—can enrich measurement-based care when deployed transparently with clear opt-outs. Finally, we show how to build registries and feedback loops so discovery findings iterate into safer, more effective, and more personal care.